#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Prolymphocytic leukaemia Lung adenocarcinoma Marginal zone lymphoma Renal transplant Precursor T-lymphoblastic lymphoma/leukaemia recurrent Langerhans' cell histiocytosis Cystic fibrosis lung Hypochondroplasia Chondrodystrophy Rectal cancer HER2 mutant non-small cell lung cancer Antisynthetase syndrome Stiff person syndrome Haemophagocytic lymphohistiocytosis Plasma cell myeloma More trials…

    Learn about Rare Diseases

    Thrombotic thrombocytopenic purpura – Basic Information Familial amyotrophic lateral sclerosis – Trials in Disease Atypical haemolytic uraemic syndrome – Treatment Bronchopulmonary dysplasia – Treatment Mitochondrial myopathy – Treatment Fragile X syndrome – Trials in Disease Primary mediastinal large B-cell lymphoma – Life with Disease Pleomorphic leiomyosarcoma – Basic Information Hereditary neuropathic amyloidosis Waldenstrom’s macroglobulinaemia recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bbp-398 ZIGAKIBART Noradrenaline Tartrate Asciminib Hydrochloride Somatropin Brimonidine Tipiracil H2-Receptor Antagonist Gemcitabine METAMIZOLE SODIUM Acalabrutinib Immunoglobulin M Ribitol Trametinib Olorofim Botensilimab Tetracaine Hydrochloride Taplucainium Chloride Egl-001 Gallium (68Ga) Chloride More therapies…

    Learn about Your Condition

    Glioblastoma Medulloblastoma Dementia Cardiac amyloidosis Delayed graft function Haemoptysis Alopecia areata Lip and/or oral cavity cancer Addison's disease Thrombocytosis Fibromyalgia Pulmonary congestion Naevus flammeus Renal impairment Tuberous sclerosis complex More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Carboplatin
    • Cyclophosphamide Monohydrate
    France

  • Randomized Study of SIR9900 for Safety and Effectiveness in Patients with VEXAS Syndrome

    Not yet recruiting

    2 1
    Investigated Diseases:
    • VEXAS syndrome
    Italy

  • Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Adrenogenital syndrome
    Investigated Drugs:
    • Crinecerfont
    Austria Bulgaria Czechia Germany Italy Portugal +3

  • Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

    Not yet recruiting

    2 1 1
    France Germany Italy Spain

  • Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Rilvegostomig
    • Pembrolizumab
    Spain

  • Effect of liraglutide on immune response to pneumococcal polysaccharide vaccine in adults with diabetes

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Diabetes mellitus
    Investigated Drugs:
    • Pneumococcal Polysaccharide Serotype 17F
    • Pneumococcal Polysaccharide Serotype 2
    • Pneumococcal Polysaccharide Serotype 20
    The Netherlands
Previous Page
1 … 673 674 675 676 677 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!